Little is known about the vasomotor effects of sirolimus, and preliminary studies using animal models have provided conflicting results. The present study was designed to determine the effects of sirolimus on vasomotor tone in human blood vessels. Human radial artery segments were cut into rings, denuded of endothelium, and placed into organ chambers for isometric tension recording. Sirolimus (10 Ϫ10 to 10 Ϫ6 M) caused concentration-dependent relaxation of human arteries contracted with U46619 (9,11-dideoxy-11␣,9␣-epoxymethanoprostaglandin F 2␣ ; 10 Ϫ8 M) [Ϫlog (M) EC 50 (pD 2 ) ϭ 7.28 Ϯ 0.1; E max ϭ 57 Ϯ 6%] or phenylephrine (10 Ϫ6 M) (pD 2 ϭ 7.16 Ϯ 0.4; E max ϭ 45 Ϯ 9%). Sirolimus-induced relaxation was unaffected by treatment with indomethacin (10 Ϫ5 M) but was nearly abolished in tissues contracted by depolarization with elevated K ϩ (60 mM). In U46619-contracted rings, the response to sirolimus was markedly inhibited in the presence of the specific ATPsensitive potassium (K ATP ) channel blocker, glyburide (10 Ϫ6 M), but was unaffected by treatment with blockers of large conductance, calcium-activated potassium channel (iberiotoxin, 10 Ϫ7 M), small conductance, calcium-activated potassium channel (apamin, 10 Ϫ6 M), or voltage-gated potassium channel (4-aminopyridine, 10 Ϫ3 M). The K ATP channel opener, aprikalim (10 Ϫ7 to 10 Ϫ5 M), caused concentration-dependent relaxations that were inhibited by glyburide (10 Ϫ6 M) and abolished in tissues contracted with elevated K ϩ (60 mM), thus confirming that K ATP channel opening causes relaxation of these arteries. These data suggest that sirolimus, at concentrations attained in vivo, causes relaxation of human arteries, and this effect is mediated by opening of K ATP channels in vascular smooth muscle. Reduced vasomotor tone is a heretofore unrecognized action of sirolimus that could potentially contribute to its efficacy in drug-eluting stents.

No abstract